Development of Novel, Non-Toxic Rifamycins That Reverse Drug Resistance in Diffuse Large B-Cell Lymphoma (DLBCL) (original) (raw)
AI-generated Abstract
The study focuses on the development of non-toxic rifamycins aimed at reversing drug resistance in patients with diffuse large B-cell lymphoma (DLBCL). It explores the mechanisms of resistance in DLBCL and demonstrates the efficacy of the novel compounds through in vitro and in vivo models. The findings highlight potential therapeutic applications and pave the way for improved treatment strategies for DLBCL patients.
Related papers
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.